Overexpression of enhancer of zests homolog 2 in lymphoma

Chinese Medical Journal

Volumn 125, Issue 20, 2012, Pages 3735-3739

  Guo, Shan qi ^a   Zhang, Yi zhuo ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Enhancer of zests homolog 2; Lymphoma; Polycomb group

Indexed keywords

3 DEAZANEPLANOCIN A; BMI1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; MICRORNA 101; MICRORNA 26A; PANOBINOSTAT; POLYCOMB GROUP PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR HOXA9;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SPECIFIC SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN; DISEASE COURSE; EPIGENETICS; GENE MUTATION; GERMINAL CENTER; HEMATOPOIETIC STEM CELL; HISTONE METHYLATION; HOX GENE; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

DISEASE PROGRESSION; EPIGENESIS, GENETIC; HISTONES; HUMANS; LYMPHOMA; METHYLATION; MUTATION; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84867903825     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.20.025     Document Type: Review

References (41)

1. Figueroa ME, Reimers M, Thompson RF, Ye K, Li Y, Selzer RR, et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One 2008; 3: e1882.
2. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011; 21: 502-517.
3. Zhou X, Ma H. Evolutionary history of histone demethylase families: distinct evolutionary patterns suggest functional divergence. BMC Evol Biol 2008; 8: 294.
4. Liu YL, Chiang YH, Liu GY, Hung HC. Functional role of dimerization of human peptidylarginine deiminase 4 (PAD4). PLoS One 2011; 6: e21314.
5. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837.
6. Martinez-Garcia E, Licht JD. Deregulation of H3K27 methylation in cancer. Nat Genet 2010; 42: 100-101.
7. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010; 116: 5247-5255.
8. Schuettengruber B, Cavalli G. Recruitment of polycomb group complexes and their role in the dynamic regulation of cell fate choice. Development 2009; 136: 3531-3542.
9. Schuettengruber B, Martinez AM, Iovino N, Cavalli G. Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol 2011; 12: 799-814.
10. Piunti A, Pasini D. Epigenetic factors in cancer development: polycomb group proteins. Future Oncol 2011; 7: 57-75.
11. Aguilo F, Zhou MM, Walsh MJ. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res 2011; 71: 5365-5369.
12. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007; 21: 525-530.
13. Fouse SD, Shen Y, Pellegrini M, Cole S, Meissner A, Van Neste L, et al. Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell 2008; 2: 160-169.
14. Prezioso C, Orlando V. Polycomb proteins in mammalian cell differentiation and plasticity. FEBS Lett 2011; 585: 2067-2077.
15. Klauke K, de Haan G. Polycomb group proteins in hematopoietic stem cell aging and malignancies. Int J Hematol 2011; 94: 11-23.
16. Martin-Perez D, Piris MA, Sanchez-Beato M. Polycomb proteins in hematologic malignancies. Blood 2010; 116: 5465-5475.
17. Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010; 10: 524.
18. de Jonge HJ, de Bont ES, Valk PJ, Schuringa JJ, Kies M, Woolthuis CM, et al. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood 2009; 114: 2869-2877.
19. Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 2010; 35: 323-332.
20. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17: 2613-2618.
21. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20: 1123-1136.
22. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 2010; 17: 801-810.
23. Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011; 26: 19-27.
24. Aoto T, Saitoh N, Sakamoto Y, Watanabe S, Nakao M. Polycomb group protein-associated chromatin is reproduced in post-mitotic G1 phase and is required for S phase progression. J Biol Chem 2008; 283: 18905-18915.
25. Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 2006; 5: 3096-3104.
26. Velichutina I, Shaknovich R, Geng H, Melnick A, Elemento O. EZH2 mediates DNA methylation-independent epigenetic silencing of a germinal center specific transcriptional program that contributes to cellular proliferation and lymphomagenesis. Blood 2009; 114: 3465.
27. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010; 116: 5247-5255.
28. Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, Weersing E, et al. The polycomb group gene EZH2 prevents hematopoietic stem cell exhaustion. Blood 2006; 107: 2170-2179.
29. Martinez-Garcia E, Licht JD. Deregulation of H3K27 methylation in cancer. Nat Genet 2010; 42: 100-101.
30. Richon VM, Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, et al. Lymphoma-associated mutations of EZH2 result in a change-of-function. Blood 2010; 116: 707.
31. Ryan RJ, Nitta M, Borger D, Zukerberg LR, Ferry JA, Harris NL, et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One 2011; 6: e28585.
32. Sander S, Bullinger L, Wirth T. Repressing the repressor: a new mode of MYC action in lymphomagenesis. Cell Cycle 2009; 8: 556-559.
33. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
34. Simon C, Chagraoui J, Krosl J, Gendron P, Wilhelm B, Lemieux S, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev 2012; 26: 651-656.
35. Sasaki D, Imaizumi Y, Hasegawa H, Osaka A, Tsukasaki K, Choi YL, et al. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 2011; 96: 712-719.
36. Nagel S, Venturini L, Marquez VE, Meyer C, Kaufmann M, Scherr M, et al. Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines. Mol Cancer 2010; 9: 151.
37. Eckerle S, Brune V, Döring C, Tiacci E, Bohle V, Sundström C, et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 2009; 23: 2129-2138.
38. Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP, et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004; 164: 873-881.
39. Xiao Y. Enhancer of zeste homolog 2: a potential target for tumor therapy. Int J Biochem Cell Biol 2011; 43: 474-477.
40. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-1696.
41. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009; 114: 2733-2743.